Jeffrey Rathmell, Ph.D.
- Co-Leader, Host-Tumor Interactions Research Program
- Cornelius Vanderbilt Professor of Immunobiology
- Professor of Pathology, Microbiology and Immunology
- Director, Vanderbilt Center for Immunobiology
Phone
Vanderbilt-Ingram Cancer Center
648-B Preston Research Building
2220 Pierce Ave
Nashville, TN 37232
648-B Preston Research Building
2220 Pierce Ave
Nashville, TN 37232
Jeffrey Rathmell, Ph.D.
- Co-Leader, Host-Tumor Interactions Research Program
- Cornelius Vanderbilt Professor of Immunobiology
- Professor of Pathology, Microbiology and Immunology
- Director, Vanderbilt Center for Immunobiology
615-322-3234
jeff.rathmell@vanderbilt.edu
Vanderbilt-Ingram Cancer Center
648-B Preston Research Building
2220 Pierce Ave
Nashville, TN 37232
648-B Preston Research Building
2220 Pierce Ave
Nashville, TN 37232
Research Program
Departments/Affiliations
Profile
Education
- Ph.D., Immunology, Stanford University, Stanford, California (1997)
- B.S., Biology, University of Northern Iowa, Cedar Falls, Iowa (1991)
Research Emphasis
Immunometabolism in inflammatory disease, cancer, and anti-tumor immunity
Research Description
There has been a growing appreciation that metabolism is intimately linked to nearly all aspects of cell function and fate. The field of immunometabolism aims to understand how metabolic pathways are regulated in immune cells, how specific metabolic programs alter immune function, and how immunity in turn may influence metabolism. The Rathmell lab focuses on how metabolic pathways influence the function and fate of lymphocytes in inflammatory diseases and anti-tumor immunity. Our work is highly interdisciplinary in which we use animal models and genetic approaches in the fields of immunology, cancer biology, and cell metabolism to understand human disease. Ultimately the goals of these projects are to exploit the specific metabolic programs of each immune cell type or activation state to selectively impact effector lymphocytes in inflammatory diseases and cancer.
Publications
- Rathmell JC. Obesity, Immunity, and Cancer. N Engl J Med. 2021 Mar 3/25/2021; 384(12): 1160-2. PMID: 33761213, DOI: 10.1056/NEJMcibr2035081, ISSN: 1533-4406.
- Ancey PB, Contat C, Boivin G, Sabatino S, Pascual J, Zangger N, Perentes JY, Peters S, Abel ED, Kirsch DG, Rathmell JC, Vozenin MC, Meylan E. Glut1 expression in tumor-associated neutrophils promotes lung cancer growth and resistance to radiotherapy. Cancer Res [print-electronic]. 2021 Mar 3/22/2021; PMID: 33753374, PII: 0008-5472.CAN-20-2870, DOI: 10.1158/0008-5472.CAN-20-2870, ISSN: 1538-7445.
- Healey DCC, Cephus JY, Barone SM, Chowdhury NU, Dahunsi DO, Madden MZ, Ye X, Yu X, Olszewski K, Young K, Gerriets VA, Siska PJ, Dworski R, Hemler J, Locasale JW, Poyurovsky MV, Peebles RS, Irish JM, Newcomb DC, Rathmell JC. Targeting In Vivo Metabolic Vulnerabilities of Th2 and Th17 Cells Reduces Airway Inflammation. J Immunol [print-electronic]. 2021 Mar 3/15/2021; 206(6): 1127-39. PMID: 33558372, PMCID: PMC7946768, PII: jimmunol.2001029, DOI: 10.4049/jimmunol.2001029, ISSN: 1550-6606.
- Levine LS, Hiam-Galvez KJ, Marquez DM, Tenvooren I, Madden MZ, Contreras DC, Dahunsi DO, Irish JM, Oluwole OO, Rathmell JC, Spitzer MH. Single-cell analysis by mass cytometry reveals metabolic states of early-activated CD8+ T cells during the primary immune response. Immunity [print-electronic]. 2021 Mar 3/6/2021; PMID: 33705706, PII: S1074-7613(21)00084-4, DOI: 10.1016/j.immuni.2021.02.018, ISSN: 1097-4180.
- Edwards DN, Ngwa VM, Raybuck AL, Wang S, Hwang Y, Kim LC, Cho SH, Paik Y, Wang Q, Zhang S, Manning HC, Rathmell JC, Cook RS, Boothby MR, Chen J. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021 Feb 2/15/2021; 131(4): PMID: 33320840, PMCID: PMC7880417, PII: 140100, DOI: 10.1172/JCI140100, ISSN: 1558-8238.
- Jia W, Poe JC, Su H, Anand S, Matsushima GK, Rathmell JC, Maillard I, Radojcic V, Imai K, Reyes NJ, Cardona DM, Li Z, Suthers A, Curry-Chisolm I, DiCioccio RA, Saban DR, Chen BJ, Chao NJ, Sarantopoulos S. BAFF Promotes Heightened BCR Responsiveness and Manifestations of Chronic GVHD after Allogeneic Stem Cell Transplantation. Blood [print-electronic]. 2021 Feb 2/3/2021; PMID: 33534893, PII: S0006-4971(21)00239-1, DOI: 10.1182/blood.2020008040, ISSN: 1528-0020.
- Rathmell JC, Rathmell WK. Pushing the boundaries with collision collaboration: the marriage of ideas. J Clin Invest. 2021 Jan 1/19/2021; 131(2): PMID: 33463534, PMCID: PMC7810468, PII: 145964, DOI: 10.1172/JCI145964, ISSN: 1558-8238.
- Ramsey HE, Greenwood D, Zhang S, Childress M, Arrate MP, Gorska AE, Fuller L, Zhao Y, Stengel K, Fischer MA, Stubbs MC, Liu PCC, Boyd K, Rathmell JC, Hiebert SW, Savona MR. BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia. Clin Cancer Res [print-electronic]. 2021 Jan 1/15/2021; 27(2): 598-607. PMID: 33148670, PII: 1078-0432.CCR-20-1346, DOI: 10.1158/1078-0432.CCR-20-1346, ISSN: 1557-3265.
- Wu H, Herr D, MacIver NJ, Rathmell JC, Gerriets VA. CD4 T cells differentially express cellular machinery for serotonin signaling, synthesis, and metabolism. Int Immunopharmacol [print-electronic]. 2020 Nov; 88: 106922. PMID: 32866787, PMCID: PMC7657973, PII: S1567-5769(20)32094-4, DOI: 10.1016/j.intimp.2020.106922, ISSN: 1878-1705.
- Beckermann KE, Hongo R, Ye X, Young K, Carbonell K, Healey DCC, Siska PJ, Barone S, Roe CE, Smith CC, Vincent BG, Mason FM, Irish JM, Rathmell WK, Rathmell JC. CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. JCI Insight. 2020 Aug 8/20/2020; 5(16): PMID: 32814710, PMCID: PMC7455120, PII: 138729, DOI: 10.1172/jci.insight.138729, ISSN: 2379-3708.
